Similarly, peptide precursors cleavable by tumor- or tissue-specific enzymes, such as prostate-specific antigen (PSA) or MMP-activating sequences, are being explored to develop prodrugs targeted to prostate cancer or the tumor microenvironment. Here, KLK3 is linked to prostate carcinoma.